Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PPID | Q08752 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6033584 | 0.82 | TP53 (0.75) | ALDH1A1MAPTEPHX1SMN1; SMN2LMNA | |
| SCHEMBL714625 | 0.82 | EPHX1 (0.77) | ALDH1A1EPHX1SMN1; SMN2LMNATSHR | |
| SCHEMBL8790625 | 0.81 | MAPT (0.70) | ALDH1A1MAPTEPHX1SMN1; SMN2LMNA | |
| SCHEMBL10937805 | 0.77 | MAPT (0.57) | ALDH1A1MAPTEPHX1SMN1; SMN2LMNA | |
| SCHEMBL30471275 | 0.77 | RIPK1 (0.61) | ALDH1A1MAPTEPHX1SMN1; SMN2TSHR | |
| SCHEMBL4765237 | 0.77 | RIPK1 (0.61) | ALDH1A1MAPTEPHX1SMN1; SMN2TSHR | |
| SCHEMBL10910476 | 0.76 | EPHX1 (0.63) | EPHX1SMN1; SMN2LMNATP53EPHX2 | |
| Trifluoroacetic Acid SCHEMBL2396352 | 0.76 | ALDH1A1 (0.60) | ALDH1A1MAPTEPHX1SMN1; SMN2LMNA | |
| SCHEMBL2172486 | 0.76 | MAPT (0.56) | ALDH1A1MAPTEPHX1SMN1; SMN2LMNA | |
| SCHEMBL20911008 | 0.76 | RAB9A (0.75) | ALDH1A1EPHX1SMN1; SMN2LMNAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111662275-B | Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof | 中国药科大学 | 2023-08-22 | — | — | CN | disclosed |
| US-9675596-B2 | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer | BALTIC BIO AB (SE) | 2017-06-13 | — | — | US | disclosed |
| US-20160128993-A1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTICGRUPPEN BIO AB (SE) | 2016-05-12 | — | — | US | disclosed |
| EP-2451794-B1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2016-01-27 | — | — | EP | disclosed |
| US-9162994-B2 | 1,2,4-thiazoloidin-3-one derivatives and their use in the treatment of cancer | BETAGENON AB (SE) | 2015-10-20 | — | — | US | disclosed |
| CN-102596923-B | 1,2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer | BALTIC BIO AB | 2015-04-29 | — | — | CN | disclosed |
| US-20120183537-A1 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BETAGENON AB | 2012-07-19 | — | — | US | disclosed |
| CN-102596923-A | 1,2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer | BETAGENON AB | 2012-07-18 | — | — | CN | disclosed |
| EP-2451794-A2 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | BALTIC BIO AB (SE) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004162-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160128993-A1 | 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, CCND3, MTNR1A | ALDH1A1 239/4885MAPT 4638/4885EPHX1 2825/4885 |
| US-20120183537-A1 | 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, CCND3, MTNR1A | ALDH1A1 271/4885MAPT 4535/4885EPHX1 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.